CEO, Karyopharm Therapeutics Inc.
Internal Medicine
Dr. Michael G. Kauffman, MD
Michael Kauffman is an expert in the field of Internal Medicine. He researched medicine at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a top medical college. Johns Hopkins University School of Medicine is ranked 3 in research and 29 in primary care medicine Dr. Michael G. Kauffman is also a published physician. He has 18 publication published. The most recent publication is: Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
Publications
- shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
- Decitabine priming enhances the anti-leukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
- KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
- KPT-330 has antitumour activity against non-small cell lung cancer.
- XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer.
- Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.
- Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
- Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas.
- CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.
- Prognostic impact and targeting of CRM1 in acute myeloid leukemia.
- CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF mutant melanoma.
- KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute ...
- Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
- Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
- Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study.
- CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.
Schools
Johns Hopkins University School of Medicine
Beth Israel Hospital Bostonma
Mass General Hosptital Ma
Doctors Specialties
- Internal Medicine
Accepted Insurances
Education
-
Massachusetts General Hospital -
Beth Israel Deaconess Medical Center -
Johns Hopkins University School of Medicine
Helpful Reviews
Similar Doctors
|
Armeen Poor |
|
|
Dr. Murali Ramadurai, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harry J. Stanger, MD |
|
|
Dr. Parul H. Kothari, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jan L. Cook, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hooshang Poor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Judith G. Packer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jean C. Smith, MD |
|
|
Dr. Barbara A. Stewart, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lucinda S. Didomenico, MD
This Doctor is OpenDoctor Recommended.
|